Exploration of Treatment Effect of Novel Hormone Therapy Combined with Local Treatment Based on PSMA PET/CT Evaluation in MHSCP Patients

For bone lesions, radiotherapy or orthopedic surgery may be selected. For lymph node lesions, radiotherapy or high-energy focused ultrasound (HIFU) maybe selected. The specific treatment plan will be determined by the researcher and based on the patient's clinical condition.

"The intervention contains gonadotropin releasing hormone analog (GnRHa) and novel hormone therapy. For GnRHa, there are 3 options available. 1. Leuprorelin/Prostap or Staladex. 2. Goserelin/Zoladex. 3. Triptorelin /LiverTox. For novel hormone therapy, there are also 3 options available. 1. Abiraterone/ ZYTIGA®. 2. Apalutamide/ERLEADA®. 3. Rezvilutamide/ARIANE®. The specific treatment plan will be designed according to patients' clinical conditions based on EAU guidelines."